[The functional mechanism of CIK cells on ovarian carcinoma cell lines SKOV3/CDDP].
OBJECTIVE
To investigate the functional mechanism of CIK cells or ovarian carcinoma cell lines SKOV3/CDDP.


METHODS
The changes of ultramicrostructure, cell cycle, apoptosis, expression of multidrug resistance-associated protein (MDR1, Topo-IIbeta) and other molecules (hB7-1, hB7-2, MHCIb, HLA-DR) of SKOV3/CDDP cells treated with or without CIK cells were detected by electron microscope, MTT and FCM. The changes of cytokine (IL-2, TNF-alpha, IFN-gamma, GM-CSF) in sera of SCID mice bearing SKOV3/CDDP cells were detected by radioimmunit and ELISA.


RESULTS
CIK cells could induce apoptosis of the SKOV3/CDDP cells by electronmicroscopic observations. The apoptosis rate in CIK group was 9.07%, and its cell cycle was arrested at S and G2/M phase (P<0.05). Compared with NS Group, the co-expression of MDR-1 and Topo-IIbeta were decreased significantly in the CIK treated group(P<0.05), and the expression of MHCIb, HLA-DR, hB7-1 and hB7-2 antigen were increased significantly (P<0.01). Compared with NS Group, the contents of IL-2, TNF-alpha, INF-gamma, GM-CSF were increased significantly (P<0.01) in SCID mice of CIK group.


CONCLUSIONS
CIK cells have several important biological effects on the ovarian carcinoma cell line SKOV3/CDDP, which may lay the foundation for further research on anti-tumor therapy.
Zhang
Hui
H
Department of Gynecology, the Fouth Affiliated Hospital, Hebei Medical University, Shijiazhuang 050011, China. zhanghui516@126.com
Zhao
Qun
Q
Zuo
Lian-Fu
LF
Ma
Hong-Jun
HJ
Li
Shu-Rong
SR
Cheng
Jian-Xin
JX
Jia
Jin-Hua
JH
Kang
Shan
S
D000818:Animals; D017209:Apoptosis / Q000276:immunology; D002453:Cell Cycle / Q000276:immunology; D045744:Cell Line, Tumor; D055612:Cytokine-Induced Killer Cells / Q000276:immunology* / Q000648:ultrastructure; D016207:Cytokines / Q000097:blood; D018432:Drug Resistance, Multiple / Q000276:immunology; D019008:Drug Resistance, Neoplasm / Q000276:immunology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000276:immunology; D006649:Histocompatibility Antigens / Q000378:metabolism; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D010051:Ovarian Neoplasms / Q000235:genetics / Q000276:immunology* / Q000473:pathology* / Q000628:therapy
D016207:Cytokines; D006649:Histocompatibility Antigens